Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis

Ohio State University40 enrolled

Overview

Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical patients during the first 24 hours after a surgical procedure. The incidence of postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about 30%, and in high-risk patients, the PONV rate could be as high as 80%. Therefore, the study design of this single arm, non-randomized, pilot study assessed the efficacy and safety profile of a triple therapy combination with palonosetron, dexamethasone and promethazine to prevent PONV in patients undergoing craniotomies under general anesthesia.

At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis. After surgery, subjects were transferred to the surgical intensive care unit (SICU) or post anesthesia care unit as clinically indicated. Ondansetron 4 mg IV was administered as primary rescue medication to subjects with PONV symptoms. PONV was assessed and collected every 24 hours for 5 days via direct interview and/or medical charts review.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Postoperative Nausea and Vomiting

Interventions

Palonosetron 0.075 mg IVDRUG

At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.

Dexamethasone 10 mg IVDRUG

At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.

Promethazine 25 mg IVDRUG

At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, 18 to 85 years of age, of any race or gender. With an American Society of Anesthesiologist (ASA) physical status of I to III who are scheduled to undergo neurological surgery requiring opening of the cranium and Dura matter under general anesthesia, at Ohio State University Medical Center and who consent in writing to participating in this study. * Post operative hospitalization expected to last at least 72 hours. * Subjects whose surgery is expected to require at least 1 hours of general anesthesia * Subjects who have a negative serum or urine pregnancy test within 1 day of surgery or who have been surgically sterilized or are postmenopausal. Exclusion Criteria: * Subjects who are prisoners, pregnant, mentally ill, under the age of 18 or over the age of 85, ASA classification of V, alcohol or drug abusers. * Subjects with known hypersensitivity to any 5-HT3 antagonist, to any agent that is part of the anesthesia regimen, or to other medications to be administered under this protocol. * Subjects who are breastfeeding. * Subjects who have had retching/vomiting or moderate to severe nausea in the 24 hours prior to anesthesia or suffer chronic nausea and/or vomiting * Subjects who have been treated with any drug or other treatment with anti-emetic efficacy within the last 24 hours prior to the start of treatment. * Subjects who have participated in a clinical trial of an investigational drug within 30 days prior to surgery. * Subjects who are participating in any other clinical study

Outcomes

Primary Outcomes

PONV Incidence

The incidence of PONV

Time frame: 24 hours after end of surgery

Secondary Outcomes

Incidence of Subjects Significant QTc Changes in the EKG

The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery

Time frame: 24 and 120 hours/discharge after end of surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.